

area. Region 9 is composed of Virginia, West Virginia, the District of Columbia, Maryland, Delaware, and Pennsylvania. The Regional Office for this region had been located in Arlington, Virginia, and was called the Washington Regional Office. On May 19, 1986, the branch office in Philadelphia was upgraded to the Regional Office for Region 9, and the Washington Regional Office was closed. The functions and duties of the Washington Regional Office are now being handled by the Philadelphia Regional Office.

Four subsections of 17 CFR Part 200 are being amended to delete references to the Washington Regional Office and add information pertaining to the new Philadelphia Regional Office.

In addition, as required by the Federal Register, certain authority citations are being amended to add citations for the sections being revised if those authorities have not been included in the citation for the subpart.

Text of Amendments

17 CFR Part 200 is amended as follows:

PART 200—[AMENDED]

Subpart A—Organization and Program Management

1. The authority citation for Part 200, Subpart A, is amended by adding the following section:

Authority: Secs. 19, 23, 48 Stat. 85, 901, as amended, sec. 20, 49 Stat. 833, sec. 319, 53 Stat. 1173, secs. 38, 211, 54 Stat. 841, 855 (15 U.S.C. 77s, 78w, 79t, 77sss, 80a-37, 80b-11). * * * § 200.11 is also issued under 11 U.S.C. 901, 1109(a).

2. Section 200.11 is amended by revising "Region 9" in paragraph (b) as follows:

§ 200.11 Headquarters Office—Regional Office relationship.

(b) * * *
Region 9. Pennsylvania, Maryland, Virginia, West Virginia, Delaware, District of Columbia—Regional Administrator, Room 2204, William J. Green, Jr. Federal Building, 600 Arch Street, Philadelphia, Pennsylvania 19106.

Subpart D—Information and Requests

3. The authority citation for Part 200, Subpart D, is amended by adding the following section:

Authority: 80 Stat. 383, as amended, 31 Stat. 54, secs. 19, 23, 48 Stat. 85, 901, as amended, sec. 20, 49 Stat. 833, sec. 319, 53 Stat. 1173, secs. 38, 211, 54 Stat. 841, 855; 5 U.S.C. 552, 15 U.S.C. 77s, 78w, 79t, 77sss, 80a-37, 80b-11. * * * § 200.80 is also issued under 5 U.S.C.

552b; Pub. L. 87-592, 76 Stat. 394, 15 U.S.C. 78d-1, 78d-2; Pub. L. 93-502; Pub. L. 93-579; 15 U.S.C. 78a et seq., as amended by Pub. L. 84-29 (June 4, 1975) and by secs. 11A, 15, 19 and 23 of Pub. L. 98-38 (June 6, 1983) (15 U.S.C. 78k-1, 78o, 78s and 78w); 11 U.S.C. 901, 1109(a).

4. Section 200.80 is amended by adding to paragraph (c)(1)(iii) the "Philadelphia Regional Office" as listed below, which will appear after the "New York Regional Office," and by removing the complete reference to and address of the "Washington Regional Office."

§ 200.80 Commission records and information.

(c)(1) * * *
(iii) * * *

Philadelphia Regional Office, Room 2204, William J. Green, Jr. Federal Building, 600 Arch Street, Philadelphia, Pennsylvania 19106, (215-597-3100). Office hours—9:00 a.m. to 5:30 p.m. e.s.t.

Subpart H—Regulations Pertaining to the Privacy of Individuals and Systems of Records Maintained by the Commission

5. The authority citation for Part 200, Subpart H, is amended by adding the following section:

Pub. L. 93-579, sec. (f), 5 U.S.C. 552(a)(f). * * * § 200.312 is also issued under Pub. L. 93-579, Sec. k, 5 U.S.C. 552a(k).

6. Section 200.303(a)(2), listing regional and branch offices, is amended by revising the name of the "Philadelphia Branch Office" to read "Philadelphia Regional Office," and by removing the complete reference to and address of the "Washington Regional Office."

7. Section 200.312 is amended by revising paragraph (a)(17), removing paragraph (a)(22), and redesignating paragraphs (a)(23) through (a)(30) as paragraphs (a)(22) through (a)(29) as follows:

§ 200.312 Specific exemptions.

(a) * * *
(17) Philadelphia Regional Office Investigatory Files; * * *
(22) Office of the General Counsel Working Files;
(23) Office of the Chief Accountant Working Files;
(24) Investigations and Actions Index;
(25) Complaint Processing System;
(26) Investor Service Complaint Index;
(27) Name-Relationship Index System;
(28) Rule 2(e) of the Commission's Rules of Practice—Appearing or Practicing Before the Commission;

(29) Division of Enforcement Liaison Working Files.

By the Commission.

Jonathan G. Katz,

Secretary.

Shirley E. Hollis,

Assistant Secretary.

January 16, 1987.

[FR Doc. 87-1694 Filed 1-23-87; 8:45 am]

BILLING CODE 8010-01-M

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

18 CFR Part 37

[Docket No. RM86-12-000]

Generic Determination of Rate of Return on Common Equity for Public Utilities

January 20, 1987.

AGENCY: Federal Energy Regulatory Commission, DOE.

ACTION: Notice of Benchmark Rate of Return on Common Equity for Public Utilities.

SUMMARY: In accordance with § 37.5, the Commission issues the update to the "advisory" benchmark rate of return on common equity applicable to rate filings made during the period February through April 1987. This rate is set at 11.20 percent.

EFFECTIVE DATE: February 1, 1987.

FOR FURTHER INFORMATION CONTACT: Ronald L. Rattey, Office of Regulatory Analysis, Federal Energy Regulatory Commission, 825 North Capitol Street, NE., Washington, DC 20426, (202) 357-8293.

SUPPLEMENTARY INFORMATION:

Benchmark Rate of Return on Common Equity for Public Utilities

On December 24, 1986, the Commission issued a final rule which amended the quarterly indexing procedure for establishing and updating the benchmark rate of return on common equity applicable to electric rate filings.¹ Based on this amended procedure, the Commission determines that the benchmark rate of return on common equity applicable to rate filings made during the period February 1 through April 30, 1987 is 11.20 percent.

¹ Generic Determination of Rate of Return on Common Equity for Public Utilities, 52 FR 11 (January 2, 1987) (Docket No. RM86-12-000) (Final Rule) (Order No. 461).

According to the amended § 37.9, each quarterly benchmark rate or return is set equal to the average cost of common equity for the jurisdictional operations of public utilities. This average cost is based on the average of the median dividend yields for the two most recent calendar quarters for a sample of 100 utilities. The average yield is used in the following formula with fixed adjustment factors (determined in the annual proceeding) to determine the cost rate:

$$k_t = 1.02Y_t + 4.63$$

where k_t is the average cost of common equity and Y_t is the average dividend yield.

The median dividend yield for the sample of utilities for the third and fourth calendar quarters of 1985 are 6.33 and 6.54 percent, respectively, for an average of 6.44 percent. Using the latter yield produces an average cost of

common equity of 11.20 percent. The attached appendix provides the supporting data for this update.

Generally, a rule becomes effective not less than 30 days after it is published in the Federal Register. A rule may become effective sooner if the agency finds that there is good cause to do so. 5 U.S.C. 553(d) (1982). The Commission finds good cause to make this rule effective February 1, 1987. Specifically, this notice is intended to supplement the generic rate of return rule announced in Order No. 461, issued December 24, 1986 and effective on February 1, 1987, by applying the method adopted in that rule to data which was not available until after January 1, 1987.

List of Subjects in 18 CFR Part 37

Electric power rates, Electric utilities, Rate of return.

In consideration of the foregoing, the Commission amends Chapter I, Title 18 of the Code of Federal Regulations, as set forth below, effective February 1, 1987.

By direction of the Commission.

Kenneth F. Plumb,

Secretary.

PART 37—[AMENDED]

1. The authority citation for Part 37 continues to read as follows:

Authority: Federal Power Act, 16 U.S.C. 791a-825r (1982); Department of Energy Organization Act 42 U.S.C. 7101-7352 (1982).

2. In paragraph (d) of § 37.9, the table is revised to read as follows:

§ 37.9 Quarterly indexing procedure.

(d) * * *

Benchmark Applicability Period (t)	Dividend Increase Adjustment Factor (a)	Expected Growth Adjustment Factor (b)	Current Dividend Yield (Y _t)	Cost of Common Equity (k _t)	Benchmark Rate of Return
February 1, 1986 to April 30, 1986	1.02	4.54	9.03	13.75	13.75
May 1, 1986 to July 31, 1986	1.02	4.54	8.37	13.08	13.25
August 1, 1986 to October 31, 1986	1.02	4.54	7.49	12.18	12.75
November 1, 1986 to January 31, 1987	1.02	4.54	6.75	11.43	12.25
February 1, 1987 to April 30, 1987	1.02	4.63	6.44	11.20	11.20

Appendix

Note: This Appendix will not be shown in the Code of Federal Regulations.

Exhibit No. and Title

- 1—Initial Sample of Utilities
- 2—Utilities Excluded From the Sample for the Indicated Quarter due to Either Zero Dividends or a Cut in Dividends for This Quarter or the Prior Three Quarters
- 3—Quarterly Dividend Yields for the Indicated Quarters for Utilities Retained in the Sample

Source of Data: Standard and Poor's Compustat Service Inc., Utility COMPUSTAT® II Quarterly Data Base.

EXHIBIT I

Note: Exhibits I, II and III will not be shown in the Code of Federal Regulations.

INITIAL SAMPLE OF UTILITIES

[10:59 Wednesday, January 7, 1987]

Utility	Ticker Symbol
Allegheny Power System	AYP
American Electric Power	AEP
Atlantic City Electric	ATE
AZP Group	AZP
Baltimore Gas & Electric	BGE
Black Hills Corp.	BKH
Boston Edison Co.	BSE
Carolina Power & Light	CPL
Centene Energy Corp.	CX
Central & South West Corp.	CSR
Central Hudson Gas & Elec.	CNH
Central Ill. Public Service	CIP
Central Louisiana Electric	CNL
Central Maine Power Co.	CTP

INITIAL SAMPLE OF UTILITIES—Continued

[10:59 Wednesday, January 7, 1987]

Utility	Ticker Symbol
Central Vermont Pub. Serv.	CV
Citicorp Inc.	CER
Cincinnati Gas & Electric	CIN
Commonwealth Edison	CWE
Commonwealth Energy System	CES
Consolidated Edison of NY	ED
Consumers Power Co.	CMS
Delmarva Power & Light	DEW
Detroit Edison Co.	DTE
Dominion Resources Inc.—VA	D
DPL Inc.	DPL
Duke Power Co.	DUK
Duquesne Light Co.	DQU
Eastern Utilities Assoc.	EUA
Empire District Electric Co.	EDE
Fitchburg Gas & Elec. Light	FGE
Florida Progress Corp.	FPC
FPL Group Inc.	FPL
General Public Utilities	GPU
Green Mountain Power Corp.	GMP
Gulf States Utilities Co.	GSU
Hawaiian Electric Inds.	HE
Houston Industries Inc.	HOU
I E Industries Inc.	IEL
Idaho Power Co.	IDA
Illinois Power Co.	IPC
Interstate Power Co.	IPW
Iowa Resources Inc.	IOR
Iowa-Illinois Gas & Elec.	IWG
IPL	IPL
Ipalco Enterprises Inc.	IPL
Kansas City Power & Light	KLT
Kansas Gas & Electric	KGE
Kansas Power & Light	KAN
Kentucky Utilities Co.	KU
Long Island Lighting	LIL
Louisville Gas & Electric	LOU
Maine Public Service	MAP
Middle South Utilities	MSU
Midwest Energy Co.	MWE
Minnesota Power & Light	MPL
Montana Power Co.	MTP
Nevada Power Co.	NVP
New England Electric System	NES

INITIAL SAMPLE OF UTILITIES—Continued

[10:59 Wednesday, January 7, 1987]

Utility	Ticker Symbol
New York State Elec & Gas	NGE
Newport Electric Corp.	NPT
Niagara Mohawk Power	NMK
Northeast Utilities	NU
Northern Indiana Public Serv.	NI
Northern States Power—MN	NSP
Ohio Edison Co.	OEC
Oklahoma Gas & Electric	OGE
Orange & Rockland Utilities	ORU
Pacific Gas & Electric	PCG
Pacificorp	PPW
Pennsylvania Power & Light	PPL
Philadelphia Electric Co.	PE
Portland General Co.	PGN
Potomac Electric Power	POM
Public Service Co. of Colo.	PSR
Public Service Co. of Ind.	PIN
Public Service Co. of NH	PNH
Public Service Co. of N. Mex.	PNM
Public Service Enterprises	PEG
Puget Sound Power & Light	PSD
Rochester Gas & Electric	RGS
San Diego Gas & Electric	SDO
Savannah Elec & Power	SAV
Scana Corp.	SCG
Sierra Pacific Resources	SRP
Southern Calif. Edison Co.	SCE
Southern Co.	SO
Southern Indiana Gas & Elec.	SIG
St. Joseph Light & Power	SAJ
Teco Energy Inc.	TE
Texas Utilities Co.	TXU
TNP Enterprises Inc.	TNP
Tucson Electric Power Co.	TEP
Union Electric Co.	UEP
United Illuminating Co.	UIL
Unitil Corp.	UTL
Utah Power & Light	UTP
Utilicorp United Inc.	UCU
Washington Water Power	WWP
Wisconsin Electric Power	WPC
Wisconsin Power & Light	WPL
Wisconsin Public Service	WPS

EXHIBIT II

UTILITIES EXCLUDED FROM THE SAMPLE FOR THE INDICATED QUARTER DUE TO EITHER ZERO DIVIDENDS OR A CUT IN DIVIDENDS FOR THIS QUARTER OR THE PRIOR THREE QUARTERS

[10:59 Wednesday, January 7, 1987]

Ticker symbol	Utility	Reason for exclusion
YEAR=86 QUARTER=3		
CMS	Consumers Power Co.	Dividend rate was zero for the quarter ending Sept. 30, 1986.
DQU	Duquesne Light Co.	Dividend rate reduced in the quarter ending June 30, 1986.
FGE	Fitchburg Gas & Elec. Light	Dividend rate was zero for the quarter ending Sept. 30, 1986.
GPU	General Public Utilities	Dividend rate was zero for the quarter ending Sept. 30, 1986.
GSU	Gulf States Utilities Co.	Dividend rate was zero for the quarter ending Sept. 30, 1986.
KGE	Kansas Gas & Electric	Dividend rate reduced in the quarter ending Dec. 31, 1985.
KLT	Kansas City Power & Light	Dividend rate reduced in the quarter ending June 30, 1986.
LIL	Long Island Lighting	Dividend rate was zero for the quarter ending Sept. 30, 1986.
MAP	Maine Public Service	Dividend rate was zero for the quarter ending Mar. 31, 1986.
MSU	Middle South Utilities	Dividend rate was zero for the quarter ending Sept. 30, 1986.
NI	Northern Indiana Public Serv.	Dividend rate was zero for the quarter ending Sept. 30, 1986.
PIN	Public Service Co of Ind.	Dividend rate was zero for the quarter ending Sept. 30, 1986.
PNH	Public Service Co of NH	Dividend rate was zero for the quarter ending Sept. 30, 1986.
N= 13		
YEAR=86 QUARTER=4		
CMS	Consumers Power Co.	Dividend rate was zero for the quarter ending Dec. 31, 1986.
DQU	Duquesne Light Co.	Dividend rate reduced in the quarter ending June 30, 1986.
FGE	Fitchburg Gas & Elec. Light	Dividend rate was zero for the quarter ending Sept. 30, 1986.
GPU	General Public Utilities	Dividend rate was zero for the quarter ending Dec. 31, 1986.
GSU	Gulf States Utilities Co.	Dividend rate was zero for the quarter ending Dec. 31, 1986.
KLT	Kansas City Power & Light	Dividend rate reduced in the quarter ending June 30, 1986.
LIL	Long Island Lighting	Dividend rate was zero for the quarter ending Dec. 31, 1986.
MAP	Maine Public Service	Dividend rate was zero for the quarter ending Mar. 31, 1986.
MSU	Middle South Utilities	Dividend rate was zero for the quarter ending Dec. 31, 1986.
NI	Northern Indiana Public Serv.	Dividend rate was zero for the quarter ending Dec. 31, 1986.
PIN	Public Service Co of Ind.	Dividend rate was zero for the quarter ending Dec. 31, 1986.
PNH	Public Service Co of NH	Dividend rate was zero for the quarter ending Dec. 31, 1986.
N= 12		

EXHIBIT III

ANNUALIZED DIVIDEND YIELDS FOR THE INDICATED QUARTER FOR UTILITIES RETAINED IN THE SAMPLE

[10:59 Wednesday, January 7, 1987]

Ticker symbol	Price, 1st month of qtr—high	Price, 1st month of qtr—low	Price, 2nd month of qtr—high	Price, 2nd month of qtr—low	Price, 3rd month of qtr—high	Price, 3rd month of qtr—low	Dividends: annual rate	Annualized dividend yield
YEAR=86 QUARTER=3								
AEP	30.000	26.250	31.500	28.000	30.750	25.625	2.260	7.878
ATE	44.375	39.125	46.625	41.750	45.250	33.750	2.620	6.288
AYP	49.500	43.250	53.500	47.625	51.875	43.500	2.920	6.057
AZP	31.250	28.375	32.000	27.500	31.875	28.000	2.720	9.117
BGE	36.250	32.250	39.875	34.750	37.750	29.875	1.800	5.125
BKH	28.000	23.625	27.000	25.375	26.000	22.000	1.140	4.500
BSE	54.000	49.000	55.750	50.000	55.500	49.000	3.440	6.589
CER	39.500	36.250	42.500	38.500	40.750	34.000	2.280	5.909
CES	43.500	38.875	45.750	40.125	45.500	37.250	2.720	6.502
CIN	28.500	24.375	31.125	26.500	30.000	24.500	2.160	7.855
CIP	30.250	25.625	30.250	28.250	29.250	24.250	1.680	6.004
CNH	38.500	32.750	39.750	36.250	39.875	34.500	2.960	8.014
CPL	38.000	32.250	37.500	34.625	37.125	33.125	2.080	5.869
CSR	39.375	33.500	42.750	37.125	42.000	35.125	2.680	6.995
CTP	34.750	31.000	37.375	32.625	37.500	31.000	2.140	6.288
CV	19.875	17.000	19.750	17.375	20.000	17.125	1.400	7.559
CWE	27.875	25.000	28.250	24.500	29.250	25.875	1.900	7.092
CX	33.250	30.625	34.875	30.625	34.750	31.250	3.000	9.213
D	25.875	24.125	26.625	23.625	27.750	22.375	2.560	10.214
DEW	49.250	41.875	52.125	47.000	49.875	43.000	2.840	6.019
DPL	37.500	33.625	38.125	34.750	37.125	30.375	2.020	5.730
DTE	28.000	23.500	28.875	26.375	29.125	23.250	2.000	7.541
DUK	17.625	16.250	18.500	16.125	18.500	16.250	1.680	9.763
ED	49.500	44.875	52.000	47.750	50.375	41.250	2.680	5.627
EDE	50.500	43.000	52.875	48.250	52.250	44.000	2.680	5.528
EUA	34.375	30.125	36.000	32.250	35.125	30.125	1.880	5.697
	37.125	33.750	37.375	33.625	37.875	31.375	2.180	5.195

ANNUALIZED DIVIDEND YIELDS FOR THE INDICATED QUARTER FOR UTILITIES RETAINED IN THE SAMPLE—Continued

[10:59 Wednesday, January 7, 1987]

Ticker symbol	Price, 1st month of qtr—high	Price, 1st month of qtr—low	Price, 2nd month of qtr—high	Price, 2nd month of qtr—low	Price, 3rd month of qtr—high	Price, 3rd month of qtr—low	Dividends: annual rate	Annualized dividend yield
FPC	45.000	38.875	47.000	42.000	44.875	35.500	2.280	5.402
FPL	35.750	31.250	38.000	34.250	35.500	28.625	2.040	6.018
GMP	28.750	26.250	30.875	26.250	30.125	28.500	1.800	6.325
HE	35.500	30.750	34.750	32.500	33.750	29.750	1.720	5.239
HOU	34.875	30.500	37.000	33.250	36.375	31.125	2.800	8.271
IDA	29.000	26.500	30.875	26.750	29.375	23.750	1.800	6.496
IEL	26.625	23.000	27.750	25.625	27.750	23.000	1.940	7.571
IOR	26.250	23.375	27.375	24.625	27.500	22.000	1.600	6.352
IPC	27.750	25.500	32.000	26.000	32.000	28.000	2.640	9.250
IPL	55.250	49.000	59.000	52.500	56.500	47.250	3.040	5.709
IPW	31.625	27.000	30.875	29.000	29.250	25.625	1.960	6.783
IWG	46.750	41.250	46.500	42.500	46.500	39.250	2.900	6.622
KAN	61.125	52.500	65.000	60.000	61.750	50.000	3.160	5.411
KU	45.125	39.250	48.125	43.000	43.750	37.250	2.520	5.895
LOU	40.875	37.250	44.375	39.875	43.500	37.750	2.600	6.403
MPL	32.875	26.500	34.875	29.000	32.875	24.000	1.520	5.063
MTP	43.250	37.125	43.375	39.125	39.750	36.125	2.480	6.232
MWE	26.000	22.750	26.000	24.125	25.500	19.500	1.480	6.172
NES	33.125	27.375	35.250	30.875	35.250	26.500	1.920	6.115
NGE	35.875	32.250	37.875	33.625	38.500	30.000	2.640	7.611
NMK	24.000	21.500	24.875	22.625	24.125	19.250	2.080	9.151
NPT	21.875	21.125	22.250	20.875	22.750	20.375	1.500	6.963
NSP	38.000	33.125	39.750	35.750	40.125	31.000	1.900	5.235
NU	25.625	20.750	28.250	24.125	26.875	22.250	1.680	6.817
NVP	25.188	21.125	24.750	22.500	24.625	19.125	1.440	6.292
OEC	20.125	18.750	22.500	19.500	22.000	18.000	1.920	9.531
OGE	37.000	31.125	38.750	35.625	37.500	32.000	2.080	5.887
ORU	37.500	34.875	40.000	36.000	38.625	31.125	2.180	5.997
PCG	25.750	22.375	27.500	24.250	27.375	22.250	1.920	7.706
PE	23.000	19.875	25.125	22.375	23.500	20.250	2.200	9.842
PEG	44.250	36.625	48.250	42.000	44.875	38.625	2.960	6.975
PGN	35.500	30.000	36.750	32.000	34.500	28.250	1.960	5.970
PNM	35.875	33.000	37.750	33.250	37.875	32.500	2.920	8.333
POM	52.125	45.875	59.250	49.250	54.375	43.125	2.360	4.658
PPL	39.125	33.375	43.375	37.750	41.875	35.250	2.600	6.761
PPW	36.750	34.000	38.000	33.625	37.875	32.000	2.400	6.784
PSD	24.000	22.000	24.625	20.750	25.250	20.750	1.760	7.687
PSR	20.375	18.750	21.375	19.625	21.375	16.000	2.000	10.213
RGS	28.875	25.375	29.125	25.750	29.875	24.750	2.200	8.061
SAJ	36.750	32.000	37.125	35.000	36.250	33.875	1.820	5.175
SAV	18.313	16.875	20.875	17.187	22.250	16.750	0.880	4.704
SCE	35.875	30.375	38.750	34.625	38.125	31.125	2.280	6.549
SCG	42.000	35.500	42.875	38.500	41.750	34.500	2.240	5.716
SDO	40.375	34.500	42.375	37.625	42.500	34.375	2.380	6.162
SIG	41.000	34.375	41.250	37.500	40.250	35.125	1.960	5.124
SO	26.125	23.375	27.250	23.750	27.000	23.000	2.040	8.133
SRP	25.750	24.000	29.000	24.375	27.750	23.750	1.720	6.674
TE	54.875	46.375	52.250	48.750	50.125	41.875	2.520	5.138
TEP	64.875	57.250	65.000	62.125	63.500	51.000	3.300	5.443
TNP	24.000	20.500	23.750	22.250	22.750	20.000	1.320	5.944
TXU	33.875	30.250	37.500	33.125	37.000	31.250	2.680	7.921
UCU	33.875	29.750	34.375	32.375	34.625	31.125	1.480	4.528
UEP	29.250	25.000	31.750	28.125	30.625	25.625	1.840	6.480
UIL	33.250	30.125	36.125	30.750	36.250	31.125	2.320	7.044
UTL	36.875	33.875	36.500	34.875	34.875	33.000	1.800	5.143
UTP	35.000	29.500	37.250	33.375	34.750	29.125	2.320	6.995
WPC	59.500	53.500	64.500	58.125	61.375	52.250	2.680	4.604
WPL	57.250	49.250	60.250	55.250	57.625	48.500	2.960	5.413
WPS	56.500	50.500	63.000	56.500	60.500	51.250	3.000	5.322
WWP	31.625	29.000	31.250	28.375	30.750	27.000	2.480	8.360

YEAR=86 QUARTER=4

AEP	30.000	26.875	30.125	27.500	29.750	27.000	2.260	7.918
ATE	40.750	37.000	41.375	38.750	40.500	37.000	2.620	6.679
AYP	49.250	45.375	48.125	46.125	49.000	43.375	2.920	6.229
AZP	29.625	28.250	29.250	27.500	29.625	28.125	2.720	9.468
BGE	36.500	32.750	36.000	34.000	36.000	33.625	1.800	5.171
BKH	25.250	23.125	25.250	22.000	23.000	20.625	1.140	4.912
BSE	25.875	23.125	26.000	24.500	27.000	25.125	1.780	7.044
CER	42.250	37.125	42.125	37.750	40.000	37.500	2.280	5.778
CES	42.750	38.750	43.500	40.250	42.625	38.000	2.720	6.638
CIN	27.875	25.625	28.000	26.250	28.125	28.250	2.160	7.994
CIP	30.000	26.000	30.750	27.875	28.375	26.875	1.680	5.934
CNH	36.500	26.625	32.625	30.250	32.250	29.375	2.960	9.468
CNL	35.625	34.000	35.250	34.250	35.250	34.125	2.080	5.986
CPL	40.125	37.625	40.250	38.750	41.625	38.625	2.680	6.785
CSR	35.875	32.875	36.000	32.625	36.250	34.000	2.140	6.184
CTP	18.500	17.000	19.000	17.625	19.500	17.875	1.400	7.671
CV	27.875	25.875	27.125	25.875	28.875	26.125	1.900	7.048
CWE	33.375	31.375	34.375	32.375	35.500	32.500	3.000	9.023
CX	25.125	23.125	24.125	22.750	23.750	22.625	2.560	10.855
D	48.250	44.000	48.375	46.500	48.000	44.000	2.960	6.363
DEW	34.500	30.750	34.125	33.125	34.250	32.625	2.020	6.079
DPL	27.250	25.000	27.500	26.000	27.750	25.500	2.000	7.547
DTE	18.250	16.000	18.125	17.000	18.500	16.375	1.680	9.669
DUK	48.250	44.000	49.000	46.125	49.375	45.000	2.680	5.707
ED	47.000	44.500	49.750	46.875	49.375	46.500	2.680	5.662
EDE	33.500	30.750	34.875	32.250	34.000	32.000	2.000	6.060
EUA	36.375	31.875	38.250	35.500	39.500	37.125	2.180	5.983

ANNUALIZED DIVIDEND YIELDS FOR THE INDICATED QUARTER FOR UTILITIES RETAINED IN THE SAMPLE—Continued

[10:59 Wednesday, January 7, 1987]

Ticker symbol	Price, 1st month of qtr—high	Price, 1st month of qtr—low	Price, 2nd month of qtr—high	Price, 2nd month of qtr—low	Price, 3rd month of qtr—high	Price, 3rd month of qtr—low	Dividends: annual rate	Annualized dividend yield
FPC	42.500	38.500	43.750	41.875	42.625	39.250	2.400	5.795
FPL	36.000	30.250	36.750	31.750	33.250	31.125	2.040	6.147
GMP	29.875	25.750	30.000	28.375	30.250	26.125	1.800	6.339
HE	33.875	31.500	33.500	31.000	33.625	31.250	1.800	5.546
HOU	34.625	31.250	35.875	33.625	36.500	34.250	2.800	8.150
IDA	29.250	26.750	29.000	26.875	29.000	26.000	1.800	6.472
IEL	25.000	23.500	25.750	24.500	25.875	23.375	1.980	8.027
IOR	26.000	22.750	25.875	23.500	25.625	24.125	1.600	6.492
IPC	30.750	28.875	31.250	29.875	31.125	28.500	2.640	8.782
IPL	26.250	24.688	27.125	25.000	26.500	23.875	1.520	5.944
IPW	28.500	25.875	29.000	27.000	28.125	26.125	1.960	7.144
IWG	46.375	42.250	45.250	42.750	45.750	43.000	2.900	6.557
KAN	57.875	53.375	60.000	57.000	57.875	53.750	3.160	5.579
KGE	20.875	18.500	22.500	20.250	23.500	21.250	1.360	6.432
KU	42.875	40.000	44.500	41.000	43.875	40.750	2.520	5.976
LOU	41.250	39.000	41.625	39.250	41.375	36.750	2.600	6.520
MPL	32.750	29.000	33.250	30.125	31.750	29.500	1.520	4.893
MTP	38.750	36.250	39.750	38.125	41.000	38.125	2.680	6.931
MWE	24.625	22.125	24.375	21.375	23.750	21.000	1.480	6.470
NES	30.750	28.000	31.250	29.875	31.875	28.000	2.000	6.676
NGE	33.250	30.500	34.250	31.750	34.250	30.250	2.640	8.154
NMK	18.750	15.500	19.125	17.375	19.125	15.625	2.080	11.829
NPT	24.375	22.125	22.625	21.500	25.000	21.250	1.500	6.575
NSP	35.750	33.250	36.875	33.750	37.250	34.125	1.900	5.403
NU	26.375	24.250	26.625	25.500	25.875	23.875	1.680	6.610
NVP	23.250	20.750	23.125	22.000	23.000	20.125	1.440	6.533
OEC	20.125	19.125	21.000	19.250	20.500	19.500	1.920	9.640
OGE	35.375	31.250	35.875	34.250	35.875	34.500	2.080	6.025
ORU	36.375	34.000	35.750	33.625	36.500	34.000	2.180	6.221
PCG	25.125	23.375	25.625	23.750	26.125	23.750	1.920	7.797
PE	23.875	21.625	24.125	22.625	23.750	22.375	2.200	9.539
PEG	42.625	39.125	43.375	40.750	42.500	39.750	2.960	7.158
PGN	32.000	27.000	34.500	31.250	33.000	28.500	1.960	6.314
PNM	36.750	34.000	35.750	33.750	36.000	33.000	2.920	8.373
POM	53.500	47.250	53.125	48.750	51.250	48.000	2.360	4.691
PPL	39.500	36.000	40.250	37.750	39.750	36.250	2.600	6.797
PPW	36.875	33.500	36.875	34.750	36.875	35.250	2.400	6.725
PSD	23.375	21.750	23.000	21.375	22.625	20.500	1.760	7.962
PSR	19.875	16.250	19.375	17.250	19.125	17.625	2.000	10.959
RGS	25.375	21.875	24.750	23.750	24.875	21.250	2.200	9.034
SAJ	35.875	32.125	39.000	35.750	38.000	37.000	1.880	5.180
SAV	22.250	18.125	23.125	19.750	22.750	19.500	0.880	4.207
SCE	35.125	31.875	35.750	33.000	36.000	33.625	2.280	6.661
SCG	39.875	36.000	39.500	37.375	39.375	36.500	2.240	5.879
SDO	36.375	33.750	37.375	35.125	37.625	33.750	2.380	6.673
SIG	39.750	38.000	39.875	37.500	40.375	37.000	1.960	5.058
SO	25.625	24.000	26.750	24.625	27.000	25.000	2.140	8.392
SRP	26.750	25.500	26.375	25.625	26.875	25.125	1.720	6.605
TE	49.750	45.875	50.125	47.000	48.750	45.500	2.520	5.268
TEP	61.375	55.625	62.000	58.625	61.875	57.625	3.300	5.544
TNP	22.625	20.250	23.250	22.000	22.875	22.000	1.320	5.955
TXU	34.750	32.250	34.750	32.375	33.500	31.250	2.680	8.085
UCU	32.108	30.515	33.625	31.000	32.750	31.375	1.451	4.549
UEP	29.750	27.375	31.000	29.000	30.500	28.125	1.920	6.555
UIL	33.500	31.000	35.500	32.250	33.500	28.375	2.320	7.171
UTL	33.375	31.125	32.500	30.625	31.375	28.750	1.800	5.752
UTP	33.250	31.125	33.375	26.875	28.875	25.625	2.320	7.771
WPC	58.250	54.500	57.000	53.000	57.750	51.750	2.680	4.840
WPL	55.000	52.000	54.500	50.750	54.000	50.000	2.960	5.616
WPS	54.750	51.500	55.375	52.000	55.000	48.250	3.000	5.680
WWP	28.625	26.125	28.750	26.375	27.250	24.875	2.480	9.185

[FR Doc. 87-1599 Filed 1-23-87; 8:45 am]

BILLING CODE 6717-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
21 CFR Parts 207 and 558

[Docket No. 77N-0076]

New Animal Drugs for Use in Animal Feeds; Definitions and General Considerations; Revised Procedures for Medicated Feed Applications; Editorial Amendments

AGENCY: Food and Drug Administration.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) revised the current procedures and requirements concerning conditions of approval for manufacture of animal feeds containing new animal drugs in a final rule published in the *Federal Register* of March 3, 1986 (51 FR 7382). This document amends the revised regulations by correcting editorial and typographical errors, and makes minor,

noncontroversial, and technical revisions.

EFFECTIVE DATES: Effective May 2, 1986, except that the provisions of 21 CFR 558.4(d), Category II, requiring the submission and approval of medicated feed applications for products formerly exempt from such requirement shall become effective March 3, 1987.

FOR FURTHER INFORMATION CONTACT: George Graber, Center for Veterinary Medicine (HFV-220), Food and Drug

Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-4438.

SUPPLEMENTARY INFORMATION: In the Federal Register of March 3, 1986 (51 FR 7382), FDA published a document that amended the animal drug regulations concerning approval for use of new animal drugs in medicated animal foods (specifically for Type A medicated articles and Type B and Type C medicated feeds). The document failed to include certain revisions in terminology, inadvertently deleted certain portions of the regulations, and failed to provide for certain numerical as well as editorial revisions. Thus, the revisions are intended to correct various errors in the final rule.

List of Subjects

21 CFR Part 207

Drugs, Reporting and recordkeeping requirements.

21 CFR Part 558

Animal drugs, Animal feeds. Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, Parts 207 and 558 are amended as follows:

PART 207—REGISTRATION OF PRODUCERS OF DRUGS AND LISTING OF DRUGS IN COMMERCIAL DISTRIBUTION

1. The authority citation for 21 CFR Part 207 is revised to read as follows:

Authority: Secs. 201, 502, 505, 506, 507, 510, 512, 701(a), 704, Pub. L. 717, 52 Stat. 1040-1042 as amended, 1050-1053 as amended, 1055, 1057 as amended, 82 Stat. 343-351 (21 U.S.C. 321, 352, 355, 356, 357, 360, 360b, 371(a), 374); sec. 351, Pub. L. 410, 58 Stat. 702 as amended (42 U.S.C. 262); 21 CFR 5.10, 5.11.

§ 207.20 [Amended]

2. Section 207.20 *Who must register and submit a drug list* is amended in paragraph (a) by revising the parenthetical phrase "(including a feed concentrate, a feed supplement, and a complete feed)" to read "(including a Type B and Type C medicated feed)".

§ 207.25 [Amended]

3. Section 207.25 *Information required in registration and drug listing* is amended in paragraph (b)(1) by revising "drug premixes" to read "Type A articles" and in paragraph (b)(6) by revising "drug premix" and "custom premix" to read "Type A medicated article".

§ 207.35 [Amended]

4. Section 207.35 *Notification of registrant; drug establishment registration number and drug listing number* is amended in paragraph (b)(2)(iii) by revising "custom premix" to read "Type A medicated article".

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

5. The authority citation for 21 CFR Part 558 continues to read as follows:

Authority: Sec. 512, 82 Stat. 343-351 (21 U.S.C. 360b); 21 CFR 5.10 and 5.83.

§ 558.3 [Amended]

6. Section 558.3 *Definitions and general considerations applicable to this part* is amended in paragraph (b)(3) in the second sentence by removing "of the Type A medicated article".

7. Section 558.4 is amended in paragraph (b) by revising the table to read as follows:

§ 558.4 Medicated feed applications.

(d) ***

CATEGORY I

Drug	Assay limits percent ¹ type A	Type B maximum (200x)	Assay limits percent ¹ type B/C ²
Aklomide.....	90-110	22.75 g/lb (5.0%).....	85-120.
Ammonium chloride.....	90-110	4.0 oz/lb (25%).....	85-115.
Amprolium with Ethopabate.....	94-114	22.75 g/lb (5.0%).....	80-120.
Bacitracin methylene disalicylate.....	85-115	25.0 g/lb (5.5%).....	70-130.
Bacitracin zinc.....	84-115	5.0 g/lb (1.1%).....	70-130.
Bambermycins.....	90-110	800 g/ton (0.09%).....	80-120/70-130.
Buquinolate.....	90-110	9.8 g/lb (2.2%).....	80-120.
Chlortetracycline.....	85-115	40.0 g/lb (8.8%).....	80-115/70-130.
Coumaphos.....	95-115	6.0 g/lb (1.3%).....	80-120.
Decoquinolate.....	90-105	2.72 g/lb (0.6%).....	80-120.
Dichlorvos.....	100-115	33.0 g/lb (7.3%).....	90-120/80-130.
Erythromycin (thiocyanate salt).....	85-115	9.25 g/lb (2.04%).....	< 20g/ton 70-115/150-50; > 20g/ton 75-125.
Fenbendazole.....	95-113	4.54 g/lb (1.0%).....	75-125.
Iodinated casein.....	85-115	20.0 g/lb (4.4%).....	75-125.
Lasalocid.....	100-120	40.0 g/lb (8.8%).....	Type B (cattle and sheep): 80-120; Type C (all): 75-125.
Monensin.....	90-110	40.0 g/lb (8.8%).....	Chickens: 75-125; Cattle: 5-10 g/ton 80-120; Cattle: 10-30 g/ton 85-115; Liq. feed: 80-120.
Nequinolate.....	95-112	1.83 g/lb (0.4%).....	80-120.
Niclosamide.....	85-20	225g/lb (49.5%).....	80-120.
Nystatin.....	85-125	5.0 g/lb (1.1%).....	75-125.
Oleandomycin.....	85-120	1.125 g/lb (0.25%).....	< 11.25 g/ton 70-130; > 11.25 g/ton 75-125.
Oxytetracycline.....	90-120	20.0 g/lb (4.4%).....	75-125/65-135.
Penicillin.....	80-120	10.0 g/lb (2.2%).....	65-135.
Penicillin.....	80-120	1.5 g/lb (0.33%).....	65-135.
Streptomycin.....	85-115	7.5 g/lb (1.65%).....	70-130.
Poloxalene.....	90-110	54.48 g/lb (12.0%).....	Liq. feed: 85-115.
Salinomycin.....	100-120	6.0 g/lb (1.3%).....	80-120.
Tylosin.....	80-120	10.0 g/lb (2.2%).....	75-125.
Virginiamycin.....	85-115	10.0 g/lb (2.2%).....	70-130.
Zoalene.....	98-104	11.35 g/lb (2.5%).....	85-115.

¹ Percent of labeled amount.

² Values given represent ranges for either Type B or Type C medicated feeds. For those drugs that have two range limits, the first set is for a Type B medicated feed and the second set is for a Type C medicated feed. These values (ranges) have been assigned in order to provide for the possibility of dilution of a Type B medicated feed with lower assay limits to make a Type C medicated feed.

CATEGORY II

Drug	Assay limits percent ¹ type A	Type B maximum (100x)	Assay limits percent ¹ type B/C ²
Amprolium	94-114	11.35 g/lb (2.5%)	80-120.
Apramycin	88-112	7.5 g/lb (1.65%)	80-120.
Arsanilate sodium	90-110	4.5 g/lb (1.0%)	85-115/75-125.
Arsanilic acid	90-110	4.5 g/lb (1.0%)	85-115/75-125.
Butynorate	90-110	17.0 g/lb (3.74%)	85-115.
Butynorate	90-110	63.45 g/lb (14.0%)	85-115.
Piperazine	90-110	49.85 g/lb (11.0%)	85-115.
Phenothiazine	90-110	263.32 g/lb (58.0%)	85-115.
Carbadox	90-110	2.5 g/lb (0.55%)	75-125.
Carbarsone	93-102	17.0 g/lb (3.74%)	85-115.
Clopidol	94-106	11.4 g/lb (2.5%)	90-115/80-120.
Dimetridazole	96-103	9.1 g/lb (2.0%)	85-120.
Famphur	100-110	5.5 g/lb (1.21%)	90-115/80-120.
Furazolidone	95-105	10.0 g/lb (2.2%)	85-115.
Halofuginone hydrobromide	80-120	272.0 g/ton (.03%)	70-125.
Hygromycin B	90-110	1,200 g/ton (0.13%)	75-125.
Ipronidazole	98-115	2.84 g/lb (0.63%) 0.00625%.	85-120/75-125; 85-120/ 80-120.
Levamisole	85-120	113.5 g/lb (25%)	85-125.
Lincomycin	90-115	10.0 g/lb (2.2%)	80-130.
Melengestrol acetate	90-110	2.0 g/ton (0.00022%)	70-120.
Morantel tartrate	90-110	66.0 g/lb (14.52%)	85-115.
Neomycin	80-120	7.0 g/lb (1.54%)	70-125.
Neomycin	80-120	7.0 g/lb (1.54%)	70-125.
Oxytetracycline	80-120	10.0 g/lb (2.2%)	65-135.
Nicarbazin	98-106	5.675 g/lb (1.25%)	85-115/80-120.
Nitarson	90-110	8.5 g/lb (1.87%)	85-120.
Nitrofurazone	90-110	10.0 g/lb (2.2%)	80-125.
Nitromide	90-110	11.35 g/lb (2.5%)	80-120.
Sulfanitran	85-115	13.6 g/lb (3.0%)	75-125.
Nitromide	90-110	11.35 g/lb (2.5%)	85-115.
Sulfanitran	85-115	5.65 g/lb (1.24%)	75-125.
Roxarsone	95-103	2.275 g/lb (0.5%)	85-120.
Novobiocin	85-115	17.5 g/lb (3.85%)	80-120.
Phenothiazine	90-110	66.5 g/lb (14.6%)	85-115.
Piperazine	90-110	165 g/lb (40.25%)	85-115.
Pyrantel tartrate	90-110	4.8 g/lb (1.1%)	75-125.
Robenidine	95-115	1.5 g/lb (0.33%)	80-120.
Ronnel	85-115	27.2 g/lb (6.0%)	80-120.
Roxarsone	95-103	2.275 g/lb (0.5%)	85-120.
Roxarsone	95-103	2.275 g/lb (0.5%)	85-120.
Aklomide	90-110	11.35 g/lb (2.5%)	85-120.
Roxarsone	95-103	2.275 g/lb (0.5%)	85-120.
Clopidol	94-106	11.35 g/lb (2.5%)	80-120.
Bacitracin methylene disalicylate	85-115	5.0 g/lb (1.1%)	70-130.
Roxarsone	95-103	2.275 g/lb (0.5%)	85-120.
Monensin	90-110	5.5 g/lb (1.2%)	75-125.
Sulfadimethoxine	95-115	5.675 g/lb (1.25%) 0.01% (combined).	85-115/75-125.
Ormetoprim (5/3)	95-115	3.405 g/lb (0.75%) 0.02% (combined).	85-115.
Sulfadimethoxine	95-115	85.1 g/lb (18.75%)	85-115/75-125.
Ormetoprim (5/1)	95-115	17.0 g/lb (3.75%)	85-115.
Sulfathoxy pyridazine	95-105	50.0 g/lb (11.0%)	85-115.
Sulfamerazine	85-115	18.6 g/lb (4.0%)	85-115.
Sulfamethazine	85-115	10.0 g/lb (2.2%)	80-120.
Chlortetracycline	85-115	10.0 g/lb (2.2%)	85-125/70-130.
Penicillin	85-115	5.0 g/lb (1.1%)	85-125/70-130.
Sulfamethazine	85-115	10.0 g/lb (2.2%)	80-120.
Chlortetracycline	85-115	10.0 g/lb (2.2%)	85-125/70-130.
Sulfamethazine	85-115	10.0 g/lb (2.2%)	80-120.
Tylosin	80-120	10.0 g/lb (2.2%)	75-125.
Sulfanitran	85-115	13.6 g/lb (3.0%)	75-125.
Aklomide	90-110	11.2 g/lb (2.5%)	85-120.
Sulfanitran	85-115	13.6 g/lb (3.0%)	75-125.
Aklomide	90-110	11.2 g/lb (2.5%)	85-120.

CATEGORY II—Continued

Drug	Assay limits percent ¹ type A	Type B maximum (100x)	Assay limits percent ¹ type B/C ²
Roxarsone.....	95-103	2.715 g/lb (0.60%).....	85-120.
Sulfantran.....	85-115	13.6 g/lb (3.0%).....	75-125.
Aklomide.....	90-110	11.2 g/lb (2.5%).....	85-120.
Roxarsone.....	95-103	2.27 g/lb (0.5%).....	85-120.
Sulfaquinoxaline.....	98-106	11.2 g/lb (2.5%).....	85-115.
Sulfathiazole.....	85-115	10.0 g/lb (2.2%).....	80-120.
Chlortetracycline.....	85-125	10.0g/lb (2.2%).....	70-130.
Penicillin.....	80-120	5.0 g/lb (1.1%).....	70-130.
Thiabendazole.....	94-106	45.4 g/lb (10.0%).....	<7% 85-115; >7% 90-110.

¹ Percent of labeled amount.² Values given represent ranges for either Type B or Type C medicated feeds. For those drugs that have two range limits, the first set is for a Type B medicated feed and the second set is for a Type C medicated feed. These values (ranges) have been assigned in order to provide for the possibility of dilution of a Type B medicated feed with lower assay limits to make a Type C medicated feed.

§ 558.5 [Amended]

8. Section 558.5 is amended by revising the section heading to read *New animal drug requirements for liquid Type B feeds*; in paragraphs (a), (b), and (c) by revising "liquid feed supplement" and "liquid feed supplements" to read "liquid Type B medicated feeds"; in paragraph (b) by revising "supplement" to read "Type B feed"; and in paragraph (c)(2) by revising "Bureau of Veterinary Medicine" to read "Center for Veterinary Medicine."

§ 558.55 [Amended]

9. Section 558.55 *Amprolium* is amended in paragraph (d)(1)(i)(b) by revising "supplement" to read "Type B feed"; in paragraph (d)(2) in the introductory text by removing "in the complete feed"; in paragraph (d)(2) in the table in item (ii) in the fourth column under "Limitations" in the first and sixth entry by revising "in item (ii)" to read "in item (i)"; and in the introductory text of paragraph (d)(3) by removing "in complete feed".

§ 558.58 [Amended]

10. Section 558.58 *Amprolium and ethopabate* is amended in paragraph (a)(2) by revising "0.5" to read "0.05".

§ 558.76 [Amended]

11. Section 558.76 *Bacitracin methylene disalicylate* is amended in paragraph (a) by revising "25, 40, or 50 percent" to read "10, 25, 40, or 50 grams per pound".

§ 558.78 [Amended]

12. Section 558.78 *Bacitracin zinc* is amended in paragraph (d)(1) in the table in items (ii) and (v) in the fourth column under "Limitations" by revising "complete feed" to read "Type C feed".

§ 558.128 [Amended]

13. Section 558.128 *Chlortetracycline* is amended in paragraph (c)(3) by revising the title of Table I "In Complete Feed" to read "In Type C Feed" and in Table II by revising the title "In Feed Supplements" to read "In Type B Feed".

§ 548.145 [Amended]

14. Section 558.145 *Chlortetracycline, procaine penicillin, and sulfamethazine* is amended in paragraph (d)(1) by revising "a complete feed" to read "a Type C feed".

§ 558.155 [Amended]

15. Section 558.155 *Chlortetracycline, procaine penicillin, and sulfathiazole* is amended in paragraph (d)(3) in the title of the table by revising "Medicated Ration" to read "Type C Feed".

§ 558.175 [Amended]

16. Section 558.175 *Clopidol* is amended in the introductory text of paragraph (c) by removing "in complete feed for animals", and in paragraphs (c)(1)(ii) and (iii) and (4)(ii) by revising "3-nitro-4-hydroxyphenylarsonic acid" to read "roxarsone".

§ 558.185 [Amended]

17. Section 558.185 *Coumaphos* is amended in the introductory text of paragraph (d) by removing "in animal feeds"; in paragraphs (d)(1)(i)(b), (2)(iii), and (3)(iii) by revising "complete feed" to read "Type C feed" and "supplement" to read "Type B feed".

18. Section 558.195 is amended in paragraph (d)(2) in the table in the fourth column under "Limitations" by revising "complete feed" and "supplement" to read "Type C feed", by combining the tables in existing paragraphs (d)(1) and (2) in a single

table under paragraph (d), by removing the introductory text of paragraph (d)(2), by revising paragraph (c), and by redesignating paragraph (d)(1) as paragraph (d) and revising it, to read as follows:

§ 558.195 *Decoquinat*.

(c) *Special considerations.* Bentonite should not be used in decoquinat feeds.

(d) *Conditions of use.* It is used as follows:

§ 558.205 [Amended]

19. Section 558.205 *Dichlorvos* is amended in paragraph (b)(3) by revising "feed supplements" and "supplements" to read "Type A articles and Type B feeds" and by removing paragraph (b)(4).

§ 558.240 [Amended]

20. Section 558.240 *Dimetridazole* is amended in the introductory text of paragraph (c) by removing "in the complete feed".

21. Section 558.248 is amended in paragraph (b) by revising "erythromycin" to read "erythromycin", by revising paragraph (a)(2), and by adding new paragraphs (a)(3), (4), and (5), to read as follows:

§ 558.248 *Erythromycin thiocyanate.*

(a) * * *

(2) 5 and 10 percent to 050604 for use in paragraphs (d)(1)(i) and (ii) of this section.

(3) 3.7 grams per pound to 000004 for use as in paragraphs (d)(1)(i) and (ii) of this section.

(4) 9.25 grams per pound to 000004 for use as in paragraph (d)(1)(v), item 3 of this section.

(5) 18.5 grams per pound to 000004 for use as in paragraph (d)(1)(v), item 1 of this section.

* * * * *

§ 558.274 [Amended]

22. Section 558.274 *Hygromycin B* is amended in the introductory text of paragraph (c)(1) by removing "in complete feed for animals".

23. Section 558.311 is amended by redesignating existing paragraphs (a), (b), (c), and (d) as paragraphs (b), (c), (d), and (e), respectively; by adding paragraph (a); by revising redesignated paragraph (e) in the table in item (3) in the fourth column under "Limitations" by changing the term "finished feed" to read "Type C feed"; and by revising redesignated paragraphs (b) and (d) and

the introductory text of paragraph (e) to read as follows:

§ 558.311 Lasalocid.

(a) *Specifications.* A minimum of 90 percent of lasalocid activity is derived from lasalocid A.

(b) *Approvals.* Type A medicated articles approved for sponsors identified in § 510.600(c) of this chapter for use as in paragraph (e) of this section as follows:

(1) 3.0, 3.3, 3.8, 4.0, 4.3, 4.4, 5.0, 5.1, 5.5, 5.7, 6.0, 6.3, 6.7, 7.2, 7.5, 8.0, 8.3, 10.0, 12.5, 15, 20, and 50 percent activity to 000004 for use as in paragraphs (e)(1), (2), (3), and (4) of this section.

(2) 15 percent activity to 000007 as provided by 000004 for use as in paragraph (e)(5) of this section.

(3) 15, 20, 33.1, and 50 percent activity to 000004 for use in cattle feeds as in paragraphs (e)(6), (7), and (9) of this section, and for use in sheep as in paragraph (e)(8) of this section.

(d) *Special considerations.* (1) Type C cattle and sheep feeds may be manufactured from lasalocid liquid Type B feeds which have a pH of 4.0 to 8.0 and bear appropriate mixing directions as follows:

(i) For liquid Type B feeds stored in recirculating tank systems: Recirculate immediately prior to use for no less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used.

(ii) For liquid Type B feeds stored in mechanical, air, or other agitation-type tank systems: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.

(2) A positionally stable lasalocid liquid Type B feed will not be subject to the requirements for mixing directions prescribed in paragraph (d)(1) of this section provided it has a pH of 4.0 to 8.0 and contains a suspending agent(s) sufficient to maintain a viscosity of not less than 300 centipoises per second for 3 months. Form FDA 1900 must indicate the pH and centipoises per second for such lasalocid liquid Type B feed.

(3) If a manufacturer is unable to meet the requirements of paragraph (d)(1) or (2) of this section, the manufacturer may secure approval of a positionally stable liquid Type B feed by (i) either filing a new animal drug application for the product or establishing a master file containing data to support the stability of its product; (ii) authorizing the agency to reference and rely upon the data in

the master file to support approval of a supplemental new animal drug application to establish positional stability; and (iii) requesting the sponsor of an approved new animal drug application to file a supplement to provide for use of its lasalocid Type A article in the manufacture of the liquid Type B feed specified in the appropriate master file. If the data demonstrate the stability of the liquid Type B feed described in the master file, the supplement new animal drug application will be approved. Approval of the supplement will not be published in the **Federal Register** because such approval will not affect or alter conditions or use of the product in the new animal drug application or the regulation. The approval will, however, provide a basis for the individual liquid feed manufacturer to submit, and for the agency to approve, a medicated feed application under section 512(m) of the act for liquid Type B feed. A manufacturer who seeks to market a positionally unstable lasalocid liquid Type B feed with mixing directions different from the standard directions established in paragraph (d)(1) of this section may also follow this procedure.

(4) If adequate information is submitted to show that a particular liquid Type B feed containing lasalocid is stable outside the pH of 4.0 to 8.0, the pH restriction described in paragraphs (d)(1) and (2) of this section may be waived.

(5) Required label statements:

(i) For liquid Type B feed (cattle and sheep): Mix thoroughly with grain and/or roughage prior to feeding. Feeding undiluted, mixing errors, or inadequate mixing (recirculation or agitation) may result in an excess lasalocid concentration which could be fatal to cattle and sheep. Do not allow horses or other equines access to Type A articles or Type B feeds containing lasalocid as ingestion may be fatal. Safety of lasalocid for use in unapproved species or breeding animals has not been established.

(ii) For Type A articles or Type B feeds (cattle and sheep): Feeding undiluted or mixing errors may result in an excess lasalocid concentration which could be fatal to cattle and sheep. Do not allow horses or other equines access to Type A articles or Type B feeds containing lasalocid as ingestion may be fatal. Safety of lasalocid for use in unapproved species or breeding animals has not been established.

(6) Lasalocid Type A medicated articles containing lasalocid dried fermentation residue are for use in cattle and sheep feed only.

(e) *Conditions of use.* It is used as follows:

* * * * *

24. Section 558.325 is amended in paragraphs (c)(3)(i) and (ix) by revising "3-nitro-4-hydroxyphenylarsonic acid" to read "roxarsone" and by revising the introductory texts of paragraphs (c)(1) and (2) to read as follows:

§ 558.325 Lincomycin.

* * * * *

(c) *Conditions of use.*—(1) *Broilers:*

* * * * *

(2) *Swine:*

* * * * *

§ 558.342 [Amended]

25. Section 558.342 *Melengestrol acetate* is amended in paragraph (a) by revising "premix" to read "Type A article", in the introductory text of paragraph (c) by removing "in or on finished feed", and in paragraphs (c)(1)(ii) and (2)(ii) by revising "feed supplement" and "supplement" to read "Type B feed".

26. Section 558.355 is amended in paragraphs (b)(3) and (f)(1)(ii), (x), (x)(b), (xi), and (xi)(b) by revising "3-nitro-4-hydroxyphenylarsonic acid" to read "roxarsone"; in paragraph (c) by revising "Liquid feed supplements" to read "liquid Type B feeds"; in paragraphs (d)(1) and (2) by revising "Finished" to read "Type C"; in paragraphs (d)(5) and (7) by revising "feed supplements" to read "Type B feeds"; in paragraphs (d)(7) and (9) by revising "premixes" to read "Type A articles"; in paragraphs (f)(1)(vi), (vii), and (xvii) by revising "§ 558.95(e)(1)(vi)", "§ 558.95(e)(1)(vii)", and "§ 558.95(e)(1)(xiii)" to read "§ 558.95(b)(1)(vi)", "§ 558.95(b)(1)(vii)", and "§ 558.95(b)(1)(xiii)", respectively; by revising paragraph (f)(3)(i)(b)(1) and (2) and (iv)(b) by revising "feed supplement", "feed supplements", "supplement", and "supplements" to read "Type B feed" or "Type B feeds"; in paragraph (f)(3)(i)(b)(2) by revising "premix" to read "Type A article", and by removing the word "[Reserved]" from paragraph (a) and adding a new paragraph (a) to read as follows:

§ 558.355 Monensin.

(a) *Specifications.* Monensin is present as monensin or the sodium salt. A minimum of 90 percent of monensin activity is derived from monensin A.

* * * * *

§ 558.365 [Amended]

26a. Section 558.365 *Nequinat* is amended in paragraph (d)(1)(ii) by revising "3-nitro-4-

hydroxyphenylarsonic acid" to read "roxarsone".

§ 558.369 [Amended]

27. Section 558.369 *Nitarosone* is amended in the introductory text of paragraph (d) by removing "in the complete feed".

§ 558.370 [Amended]

28. Section 558.370 *Nitrofurazone* is amended in the introductory text of paragraph (b) by removing "in the complete feed".

§ 558.376 [Amended]

29. Section 558.376 *Nitromide and sulfanitran* is amended in the introductory text of paragraph (c) by removing "in the complete feed" and in paragraphs (c)(1)(ii) and (2)(ii) by revising "premises" to read "Type A articles".

§ 558.430 [Amended]

30. Section 558.430 *Nystatin* is amended in the introductory text of paragraph (c) by removing "in the complete feed".

31. Section 558.435 is amended by revising paragraph (c) to read as follows:

§ 558.435 Oleandomycin.

(c) *Special considerations.* Do not use bentonite in Type B or Type C medicated feeds containing oleandomycin. Oleandomycin refers to oleandomycin or feed-grade oleandomycin.

§ 558.450 [Amended]

32. Section 558.450 *Oxytetracycline* is amended in paragraph (b) by revising "amount of oxytetracycline" to read "amount of mono-alkyl (C₈-C₁₈) trimethylammonium oxytetracycline" and in paragraph (d)(1) in Table 1 in the title by removing the word "complete".

§ 558.460 [Amended]

33. Section 558.460 *Penicillin* is amended in the introductory text of paragraph (c)(1) by removing "in the complete feed for animals".

34. Section 558.464 is amended in paragraph (b)(2) by revising "premix" to read "Type A article" and by revising the second sentence to read as follows:

§ 558.464 Poloxalene.

(b) * * *

(2) * * * This may be accomplished by adding the Type A article to a small quantity of feed, mixing thoroughly, then adding this mixture to the remaining feed and again mixing thoroughly. * * *

§ 558.465 [Amended]

35. Section 558.465 is amended by revising the section heading to read *Poloxalene free-choice liquid Type C feed*, in paragraphs (b) (1), (2), (3), and (4) by revising "feed supplement" and "supplement" to read "Type C feed", and in paragraph (b)(3) by revising "premix" to read "Type A article".

§ 558.485 [Amended]

36. Section 558.485 *Pyrantel tartrate* is amended in paragraphs (e) (1)(ii), (2)(ii), (3)(ii), and (4)(ii) by revising "complete feed" to read "Type C feed", in paragraph (e)(3)(ii) by revising "As a single therapeutic treatment" to read "As sole ration for a single therapeutic treatment", and in paragraphs (e) (10)(ii) and (11)(ii) by revising "(f)(2) (i), (ii), or (iii)" to read "(c)(2) (i), (ii), or (iii)".

§ 558.515 [Amended]

37. Section 558.515 *Robenidine hydrochloride* is amended in paragraph (b) by revising "Finished feed" to read "Type C feed", and in paragraph (d)(1)(iii) by removing "(3-nitro-4-hydroxyphenylarsonic acid)".

§ 558.525 [Amended]

38. Section 558.525 *Ronnel* is amended in paragraphs (b)(1) and (2)(ii) by revising "medicated concentrate" and "medicated feed concentrate" to read "Type B feed"; in paragraph (b)(2)(i) by revising "feed additive supplements" and "supplements" to read "Type B feeds"; and in paragraphs (d) (1)(ii), (2)(ii), (3)(ii), (4)(ii), and (5)(ii) by revising "feed supplement" and "mineral supplement" to read "Type B feed" and "mineral Type B feed", respectively.

§ 558.526 [Amended]

39. Section 558.526 is amended by revising the section heading to read *Ronnel liquid Type B feed*, in paragraph (a) by revising "liquid premix" and "liquid feed supplement" to read "liquid Type A article" and "liquid Type B feed", respectively, by removing paragraph (b) and marking it reserved, and in paragraphs (d) (1) and (2) by revising "liquid feed supplement" to read "liquid Type B feed".

§ 558.530 [Amended]

40. Section 558.530 *Roxarsone* is amended in paragraphs (d)(1)(iii) and (2)(i)(b) by removing "as a complete feed".

41. Section 558.575 is amended in paragraph (c)(1)(ii) by revising "3-nitro-4-hydroxyphenylarsonic acid" to read "roxarsone" and by revising paragraph (a) to read as follows:

§ 558.575 Sulfadimethoxine, ormetoprim.

(a) *Approvals.* Type A medicated articles to sponsors as identified in § 510.600(c) of this chapter for uses as in paragraph (c) of this section as follows:

(1) 25 percent sulfadimethoxine and 15 percent ormetoprim to 000004 for use for poultry as in paragraphs (c)(1), (2), (3), and (4) of this section.

(2) 25 percent sulfadimethoxine and 5 percent ormetoprim to 000004 for use for fish as in paragraphs (c)(5) and (6) of this section.

* * *

§ 558.579 [Amended]

42. Section 558.579 *Sulfaethoxyypyridazine* is amended in paragraph (c)(1)(iii) by removing "in complete feed".

§ 558.586 [Amended]

43. Section 558.586 *Sulfaquinoxaline* is amended by removing paragraph (e)(2) and marking it "[Reserved]" and in paragraph (f) by removing "in complete feed" wherever it appears.

§ 558.615 [Amended]

44. Section 558.615 *Thiabendazole* is amended in paragraph (a) by revising "liquid Type C medicated feed article" to read "liquid Type B feed", in paragraph (b) by revising "foods" to read "feed", and in paragraph (d)(5)(iii) by removing "In complete feed."

§ 558.635 [Amended]

45. Section 558.635 *Virginiamycin* is amended in paragraph (e)(2) by revising "premix" to read "Type A article" and by revising "complete feed" to read "Type C feed" and in the introductory texts of paragraphs (f)(1) and (2) by removing the phrase "in complete feeds".

46. Section 558.680 is amended in paragraph (c)(1) in the table in the fourth column under "Limitations" under entry (i) by removing the phrase "In complete feed only;" wherever it appears and by revising the introductory text of paragraph (c)(1) to read as follows:

§ 558.680 Zoalene.

* * *

(c) *Conditions of use*—(1) *Chickens and turkeys*:

* * *

Dated: January 15, 1987.

John M. Taylor,
Associate Commissioner for Regulatory Affairs.

[FR Doc. 87-1409 Filed 1-23-87; 8:45 am]

BILLING CODE 4160-01-M